On March 12, 2025, AIFA published the draft document on the “Evaluation Criteria for the Attribution of Therapeutic Innovation and the Management of Antiinfective Agents for Multidrug-Resistant
Si è concluso con successo PharmaTrend 2025 un evento che ha riunito, il 12 ed il 13 marzo 2025 a Grottaferrata (Roma) professionisti e persone
Il 12 marzo 2025, AIFA ha pubblicato la bozza del documento sui “𝗖𝗿𝗶𝘁𝗲𝗿𝗶 𝗱𝗶 𝘃𝗮𝗹𝘂𝘁𝗮𝘇𝗶𝗼𝗻𝗲 𝗽𝗲𝗿 𝗹’𝗮𝘁𝘁𝗿𝗶𝗯𝘂𝘇𝗶𝗼𝗻𝗲 𝗱𝗲𝗹𝗹’𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗶𝘁𝗮̀ 𝘁𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝗮 𝗲 𝘀𝘂𝗹𝗹𝗮 𝗴𝗲𝘀𝘁𝗶𝗼𝗻𝗲 𝗱𝗲𝗴𝗹𝗶 𝗮𝗴𝗲𝗻𝘁𝗶 𝗮𝗻𝘁𝗶𝗻𝗳𝗲𝘁𝘁𝗶𝘃𝗶
The new European Regulation on Health Technology Assessment (HTA-R) 2021/2282 officially came into force on January 12, 2025, marking a significant step in the creation
On 28 November 2024, Pharma Value collaborated with AstraZeneca to organise an in-house training day of great innovative value. An event that
On 4-5 December 2024, Pharma Value participated in the X National Congress ISPOR Italy - Rome Chapter with two scientific contributions, one of which was selected
Aggiornamento 20 dicembre 2024 Il 28 dicembre 2024, il Senato della Repubblica ha approvato in via definitiva la Legge di Bilancio per il 2025. Il
Rome, 16 October 2024 - In the context of rare diseases, orphan drugs play a crucial role because they treat conditions for which there are no
Clarification of AIFA Administrative Sanctions The law recognises that AIFA - as the drug regulatory authority - has the power to apply fines
On 19 and 20 June, the 3rd National Congress of the Ispor Roma for Future GIRF group was held in Bologna, confirming its role
